Researchers at Pulmonary Associates today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally invasive option for those suffering with advanced widespread emphysema.
The trial focuses on airway bypass, a catheter-based bronchoscopic procedure designed to reduce lung hyperinflation and shortness of breath (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs.
During the minimally invasive procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by Exhale Drug-Eluting Stents – manufactured by Broncus Technologies, Inc. The trial procedures will take place at the John C. Lincoln North Mountain Hospital.
“We are excited to be part of this study because currently there are limited treatment options for patients with severe emphysema. Patients struggle with each breath,” states Bernard Levine, MD, Principal Investigator of the study at Pulmonary Associates. “If we can reduce hyperinflation and improve lung function with airway bypass, patients will be able to breathe easier leading to a better quality of life.”
Emphysema, also known as COPD, is a characterized by a chronic, progressive, and irreversible destruction of lung tissue. The lungs lose their natural elasticity and are unable to exhale effectively, leading to air trapping within the lungs and lung overinflation. Breathing becomes inefficient and patients have to work very hard just to breathe – making normal activities, like walking, eating or even bathing, difficult. There are few treatment options for most patients with severe emphysema and there is no cure.